Strategy and TPP
SCIO
SCIO Helps Early Stage Biotech Company Evaluation
January 24th, 2019 | Strategy and TPP
Welcome to BBCR’s New Website!
December 7th, 2018 | Strategy and TPP
Categories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- Why Rare Disease Drug Development Requires a Different Clinical Strategy
- Why do orphan drug launches require specialized strategic planning?
- BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
- BBCR’s mission is to support domestic and international pharma, biotech, and device companies by nurturing their products’ strengths, while improving efficiency and safety. We specialize in strategy and provide early clinical research services to enable informed, timely decision-making for our clients.
- BBCR brings deep expertise in early-stage development, including Phase 1 and Phase 2 process and strategy, spanning pre-clinical work through pre-IND. Our early drug development capabilities encompass clinical strategy and planning, including the creation of target product profiles and the design of clinical protocols.